|
Adalimumab Injection is used for the treatment of Rheumatoid Arthritis (moderate to severe active RA & severe active and progressive RA) for which the phase 3 clinical trial has been successfully completed in Q3 2022. This formulation will contribute to increased patient comfort based on reduced injection volume. This achievement underscores the company's commitment to development of biosimilars and its mission to improve global healthcare outcomes.
SBPL has been working on development of biosimilars catering to different therapeutic areas such as Immunology, Oncology, Ophthalmology, among which, Adalimumab is the first Biosimilar from Shilpa Biologicals.
The company said that the product will be manufactured and supplied from its biologics manufacturing unit located in Dharwad, Karnataka.
Meanwhile, the company has received approval from CDSCO, New Delhi for manufacturing and sale of Lenvatinib capsules, 12, 18 and 24 mg in India. Shilpa will commercialize the product under the brand name Lenshil.
Lenshil is a bioequivalent and pharmaceutically equivalent version of the brand product Lenvima of Eisai, USA. Lenvatinib is used to treat a certain type of thyroid cancer that has returned or that has spread to other parts of the body.
Shilpa Medicare is a global brand in manufacturing and supplying of affordable API and formulation globally in different regulated markets.
The company reported a consolidated net loss of 8.04 crore in Q4 FY23 as against a net profit of Rs 29.55 crore posted in Q4 FY22. Net sales declined 22.6% year on year to Rs 263.56 crore during the quarter.
|